GlassScriptPhysician profile
Devyn Rohlfs Rivera
NPI 1700380078
$3,138.11
in general payments reported to CMS, 2019-2025
11 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2023: $1,025 · 2024: $406 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,446 · Food and Beverage: $1,407 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,446.00 |
| Food and Beverage | $1,406.67 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,949.57 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $406.57 | 2022-2024 | Cuvitru, Takhzyro |
| Astrazeneca Pharmaceuticals LP | $187.59 | 2023-2024 | Tezspire, Fasenra |
| Grifols Shared Services North America, INC. | $186.75 | 2024 | Xembify |
| Grifols USA, LLC | $124.63 | 2023-2024 | Xembify |
| Csl Behring | $97.13 | 2023-2024 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $64.27 | 2023-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Glaxosmithkline, LLC. | $31.22 | 2025 | Nucala |
| Amgen INC. | $19.34 | 2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $16.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devyn Rohlfs Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.